ストックスクリーナーアプリを入手
26.73
4.77%
-1.34
アフターアワーズ：
26.73
Harrow Inc (HROW) 最新ニュース
Harrow Inc.: Opaleye management sells $150,055 in stock By Investing.com - Investing.com India
Harrow Inc.: Opaleye management sells $150,055 in stock - Investing.com
Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Insider Monkey
Harrow to Present at Two Investor Conferences in May - Business Wire
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock - Benzinga
Harrow Health, Inc. (NASDAQ:HROW) Q1 2025 Earnings Call Transcript - Insider Monkey
Harrow (HROW) Faces Price Target Cut Amid Q1 Earnings Miss | HRO - GuruFocus
HROW Stock Price Target Raised to $60 by Analyst | HROW Stock Ne - GuruFocus
Where Harrow Stands With Analysts - Benzinga
HROW Stock Update: Analyst Raises Price Target to $60 | HROW Sto - GuruFocus
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates - MSN
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Reven - GuruFocus
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... By GuruFocus - Investing.com Canada
Harrow Health Reports Strong Q1 2025 Revenue Growth - TipRanks
Harrow Announces First-Quarter 2025 Financial Results - BioSpace
Transcript : Harrow, Inc., Q1 2025 Earnings Call, May 09, 2025 - marketscreener.com
Harrow Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Harrow: Q1 Earnings Snapshot - CT Insider
Harrow Health Q1 2025 slides: revenue up 43% as ophthalmic portfolio expands - Investing.com
Harrow Health (HROW) Reports Q1 Revenue Miss Despite Growth - GuruFocus
Harrow Inc (HROW) Q1 2025 Earnings: EPS of -$0.50 Misses Estimate, Revenue at $47.8M Below Forecast - GuruFocus
Earnings Flash (HROW) HARROW INC. Reports Q1 Loss $0.38 Per Share - marketscreener.com
Harrow (HROW) Sees Promising Revenue Growth and Expansion Plans - GuruFocus
HROW Forecasts Surpassing $280 Million Revenue by 2025 | HROW St - GuruFocus
HROW Forecasts Surpassing $280 Million Revenue by 2025 | HROW Stock News - GuruFocus
Harrow (HROW) Sees Promising Revenue Growth and Expansion Plans | HROW Stock News - GuruFocus
Harrow Inc (HROW) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Harrow to Report First Quarter 2025 Financial Results After Mark - GuruFocus
Examining the Future: Harrow's Earnings Outlook - Nasdaq
What To Expect From Harrow Inc (HROW) Q1 2025 Earnings - Yahoo Finance
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 - Business Wire
Invesco Ltd. Lowers Position in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow, Inc. (NASDAQ:HROW) Shares Sold by Wells Fargo & Company MN - Defense World
Harrow Inc (HROW) Shares Gap Down to $24.695 on Apr 28 - GuruFocus
Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol - MSN
JPMorgan Chase & Co. Lowers Stock Position in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic L - GuruFocus
Harrow Authorizes Nordic Group Unit to sell Generic Version of Maxitrol eye Treatment - marketscreener.com
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) - Morningstar
LPL Financial LLC Has $699,000 Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives Propel Success - GuruFocus
Harrow Inc (NASDAQ: HROW) Jumps 2.74%: The Most Likely Path Going Forward - Stocksregister
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients - Business Wire
4.50%
0.04%
大文字化:
|
ボリューム (24 時間):